Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533228 | 0.89 | ACKR3 (0.42) | ACKR3TBK1CYP3A4KDM4EPOLB | |
| SCHEMBL13391102 | 0.86 | ACKR3 (0.51) | ACKR3 | |
| SCHEMBL13390971 | 0.85 | ACKR3 (0.42) | ACKR3TBK1CYP3A4 | |
| SCHEMBL13391231 | 0.85 | ACKR3 (0.46) | ACKR3TBK1CYP3A4KDM4E | |
| SCHEMBL12533225 | 0.85 | ACKR3 (0.48) | ACKR3TBK1IGF1R | |
| SCHEMBL13060396 | 0.85 | ACKR3 (0.45) | ACKR3TBK1 | |
| SCHEMBL13391112 | 0.85 | ACKR3 (0.49) | ACKR3TBK1CYP3A4KDM4E | |
| SCHEMBL8225788 | 0.83 | GSK3B (0.47) | TBK1CYP3A4KDM4EPOLB | |
| SCHEMBL13391316 | 0.83 | ACKR3 (0.48) | ACKR3TBK1 | |
| SCHEMBL13409718 | 0.83 | ACKR3 (0.48) | ACKR3TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | GPR119, OXER1, INSR | ACKR3 801/4885TBK1 3752/4885CYP3A4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.